Skip to content
Peptigraph home

RENEW 1: Cagrilintide Phase 3 trial (NCT07220642)

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Registry record checked

At a glance

Phase
Phase 3
Status
Active, not recruiting
Enrolment
300
estimated
Start
5 Nov 2025 (actual)
Primary completion
11 May 2027 (estimated)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT07220642 study arms
ArmTypeInterventionsDescription
CagrilintideExperimentalDrug: CagrilintideParticipants will receive cagrilintide subcutaneously once weekly for 64 weeks.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.
Endpoints

Primary endpoint

NCT07220642 primary outcomes
MeasureTime frame
Relative change in body weightFrom baseline (week 0) to end of treatment (week 64)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07220642 secondary outcomes
MeasureTime frame
Number of participants with achievement of greater than or equal to (>=) 10 percent (%) body weight reduction (yes/no)From baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of >= 15 % body weight reduction (yes/no)From baseline (week 0) to end of treatment (week 64)
Change in waist circumferenceFrom baseline (week 0) to end of treatment (week 64)
Ratio to baseline in triglyceridesFrom baseline (week 0) to end of treatment (week 64)
Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)From baseline (week 0) to end of treatment (week 64)
Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function scoreFrom baseline (week 0) to end of treatment (week 64)
Change in Systolic Blood Pressure (SBP)From baseline (week 0) to end of treatment (week 64)
Change in body weightFrom baseline (week 0) to end of treatment (week 64)
Number of participants with achievement of >= 5 % body weight reduction (yes/no)From baseline (week 0) to end of treatment (week 64)
Change in SF-36v2® Health Survey Acute (SF-36v2® Acute) physical component summary scoreFrom baseline (week 0) to end of treatment (week 64)
Change in SF-36v2® mental component summary scoreFrom baseline (week 0) to end of treatment (week 64)
Change in IWQOL-Lite-CT total scoreFrom baseline (week 0) to end of treatment (week 64)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.